** Shares of drugmaker BridgeBio Pharma BBIO.O rise 2.7% to $39.67
** Brokerage H.C. Wainwright raises PT to $56 from $53
** Believe BBIO's rare heart disease drug, acoramidis, could reach annualized revenue run rate of more than $1 billion in mid- to late 2027 in the U.S. — H.C. Wainwright
** Acoramidis reduced incidence of atrial fibrillation events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), BBIO said in May
** Believe that this evidence, coupled with the growing proof that increased TTR stabilization extent is closely linked to favorable outcomes, should accelerate acoramidis market adoption — brokerage
** BBIO has fallen 8.3% YTD, as of last close
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。